- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 415 | GlobeNewswire (Europe) | High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine... ► Artikel lesen | |
| 13.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 278 | GlobeNewswire (Europe) | Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 16.12.25 | MAIA Biotechnology announces $1.51M private placement | 2 | Seeking Alpha | ||
| 16.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $1.51 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | 179 | GlobeNewswire (Europe) | CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA),... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer | 380 | GlobeNewswire (Europe) | Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential | 4 | GlobeNewswire (USA) | ||
| 10.12.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | MAIA Biotechnology, Inc.: MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach | 127 | GlobeNewswire (Europe) | CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) - The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade... ► Artikel lesen | |
| 01.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Directors | 1 | GlobeNewswire (USA) | ||
| 21.11.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 | 301 | GlobeNewswire (Europe) | Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO, Nov. 21, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 20.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Maia Biotechnology stellt Studiendaten auf der SITC-Konferenz 2025 vor | 1 | Investing.com Deutsch | ||
| 07.11.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.10.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 245 | GlobeNewswire (Europe) | Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the... ► Artikel lesen | |
| 14.10.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 128,98 | -0,05 % | Gilead wins favorable U.S. label update for Yescarta | ||
| ABBVIE | 189,20 | +0,11 % | Aktien New York Ausblick: Keine Tech-Erholung - Eli Lilly steigen kräftig | NEW YORK (dpa-AFX) - Mit Blick auf den Technologiesektor dürften sich die Investoren an den US-Börsen am Mittwoch zurückhalten. Der Nasdaq 100 Index, der am Vortag deutlich gefallen war, dürfte sich... ► Artikel lesen | |
| ABBOTT LABORATORIES | 93,98 | +0,23 % | Abbott Reports Positive 12-month Results From VOLT-AF IDE Study | NORTH CHICAGO (dpa-AFX) - Abbott (ABT) announced clinical data from two presentations at AF Symposium in Boston that demonstrate the strong safety and efficacy of the company's minimally invasive... ► Artikel lesen | |
| SCHOTT PHARMA | 14,200 | +0,85 % | JEFFERIES stuft Schott Pharma auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Schott Pharma mit einem Kursziel von 15,50 Euro auf "Hold" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 66,17 | -0,60 % | Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect | ||
| ASSEMBLY BIOSCIENCES | 22,400 | +1,36 % | Assembly Biosciences: Top-Favorit 2026 - darum bin ich wieder voll dabei! | Alte Liebe rostet nicht: Nach zwischenzeitlich +412% Kursgewinn im vergangenen Jahr und massiven Gewinnmitnahmen habe ich mich als Ex-Großaktionär erneut in erheblichem Umfang bei Assembly Biosciences... ► Artikel lesen | |
| PENTIXAPHARM | 1,842 | -3,05 % | EQS-News: Pentixapharm Holding AG: Pentixapharm gibt fachlich begutachtete Phase-2-Ergebnisse bekannt, die die PENTIXAFOR-PET als nicht-invasive Alternative zur Nebennierenvenenkatheterisierung bei primärem Aldosteronismus ... | EQS-News: Pentixapharm Holding AG
/ Schlagwort(e): Studienergebnisse/Studie
Pentixapharm gibt fachlich begutachtete Phase-2-Ergebnisse bekannt, die die PENTIXAFOR-PET als nicht-invasive... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,743 | +1,22 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 152,25 | -1,36 % | Should You Buy Axsome Therapeutics Stock Before Feb. 23? | ||
| MEDPACE | 458,60 | +0,07 % | A Look at Medpace Holdings' Upcoming Earnings Report | ||
| ZEALAND PHARMA | 54,82 | +0,29 % | Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy | Press release - No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark's... ► Artikel lesen | |
| UNITED THERAPEUTICS | 410,20 | -0,15 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| UCB | 262,50 | -0,15 % | UCB announces new positive data on Bimzelx in hidradenitis suppurativa | ||
| MADRIGAL PHARMACEUTICALS | 401,30 | -0,62 % | Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth | ||
| BRIDGEBIO PHARMA | 57,98 | +0,73 % | BridgeBio shares slide amid report that Pfizer will withdraw Vyndamax EU patent |
Das Unternehmen MAIA BIOTECHNOLOGY INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,085 (+4,46 %) liegt der Kurs bei 1,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.